Ownership Capital B.V. Sells 162,860 Shares of DexCom, Inc. (NASDAQ:DXCM)

Ownership Capital B.V. lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 761,810 shares of the medical device company's stock after selling 162,860 shares during the quarter. DexCom accounts for approximately 1.6% of Ownership Capital B.V.'s investment portfolio, making the stock its 21st biggest holding. Ownership Capital B.V. owned 0.20% of DexCom worth $51,072,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of DXCM. Envestnet Portfolio Solutions Inc. raised its holdings in shares of DexCom by 2.3% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 26,721 shares of the medical device company's stock worth $3,706,000 after purchasing an additional 601 shares during the period. Quantbot Technologies LP bought a new stake in DexCom during the 1st quarter valued at $853,000. Empowered Funds LLC raised its holdings in DexCom by 30.7% during the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company's stock valued at $765,000 after acquiring an additional 1,295 shares during the period. Stonebrook Private Inc. bought a new stake in DexCom during the 1st quarter valued at $309,000. Finally, Meeder Advisory Services Inc. raised its holdings in DexCom by 9.9% during the 1st quarter. Meeder Advisory Services Inc. now owns 5,295 shares of the medical device company's stock valued at $734,000 after acquiring an additional 476 shares during the period. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of analyst reports. Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a report on Friday, October 25th. Baird R W lowered shares of DexCom from a "strong-buy" rating to a "hold" rating in a research report on Friday, July 26th. JPMorgan Chase & Co. boosted their price target on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Sanford C. Bernstein boosted their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Finally, Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, August 23rd. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average target price of $104.59.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 426 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by corporate insiders.

DexCom Stock Up 1.5 %

DXCM traded up $1.05 during midday trading on Friday, reaching $69.96. The company's stock had a trading volume of 3,153,680 shares, compared to its average volume of 4,825,686. The firm has a market capitalization of $27.33 billion, a price-to-earnings ratio of 41.89, a PEG ratio of 2.10 and a beta of 1.17. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock's 50-day moving average is $69.66 and its 200-day moving average is $93.42.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.